Published in Isr Med Assoc J on May 01, 2012
Antiphospholipid syndrome and antiphospholipid antibodies in children: the two sides of the coin. Isr Med Assoc J (2012) 0.76
International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis (2013) 3.99
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum (2002) 3.96
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum (2011) 3.81
Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum (2013) 2.25
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis (2012) 2.21
Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med (2002) 2.17
Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis (2013) 2.11
Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis (2010) 2.09
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum (2004) 1.89
Catastrophic antiphospholipid syndrome: where do we stand? Arthritis Rheum (2003) 1.79
Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther (2006) 1.78
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis (2012) 1.67
Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients. Medicine (Baltimore) (2003) 1.58
Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum (2006) 1.53
Vascular involvement in Behçet's disease. Isr Med Assoc J (2002) 1.53
Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine (Baltimore) (2005) 1.46
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis (2014) 1.45
Preventing death in the catastrophic antiphospholipid (Asherson) syndrome. Isr Med Assoc J (2007) 1.44
Triple association between hepatitis C virus infection, systemic autoimmune diseases, and B cell lymphoma. J Rheumatol (2004) 1.44
Efficacy of cyclophospamide in the treatment of interstitial lung disease associated with systemic sclerosis. Arch Bronconeumol (2011) 1.42
Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) (2002) 1.37
Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics (2008) 1.20
Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore) (2006) 1.18
Etiopathogenesis of Behcet's disease. Autoimmun Rev (2009) 1.11
Immunopathogenesis of vitiligo. Autoimmun Rev (2011) 1.11
Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol (2015) 1.09
Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. Nat Rev Rheumatol (2010) 1.08
Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors. Semin Thromb Hemost (2008) 1.08
Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, followup study. Arthritis Rheum (2005) 1.07
Adalimumab for the treatment of Behçet's disease: experience in 19 patients. Rheumatology (Oxford) (2012) 1.05
Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev (2013) 1.04
Pathophysiology of Sjögren's syndrome. Arch Med Res (2006) 1.02
Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin Arthritis Rheum (2004) 1.00
Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. Semin Arthritis Rheum (2008) 1.00
Factors influencing polyautoimmunity in systemic lupus erythematosus. Autoimmun Rev (2009) 0.99
Anti-glomerular basement membrane antibodies. Isr Med Assoc J (2014) 0.99
Catastrophic antiphospholipid syndrome and sepsis. A common link? J Rheumatol (2007) 0.99
Autoantibodies and prediction of reproductive failure. Am J Reprod Immunol (2006) 0.98
Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford) (2005) 0.98
Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment. J Clin Rheumatol (2002) 0.97
Class III-IV proliferative lupus nephritis and pregnancy: a study of 42 cases. Am J Reprod Immunol (2005) 0.97
Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol (2004) 0.96
Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis (2011) 0.96
Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev (2011) 0.95
The multiple autoimmune syndromes. A clue for the autoimmune tautology. Clin Rev Allergy Immunol (2012) 0.95
Relapsing catastrophic antiphospholipid syndrome: report of three cases. Semin Arthritis Rheum (2007) 0.95
Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum (2006) 0.95
Therapeutic options in autoimmune myasthenia gravis. Autoimmun Rev (2007) 0.95
Treatment of B-cell lymphoma with rituximab in two patients with Sjögren's syndrome associated with hepatitis C virus infection. Lupus (2004) 0.95
Prevalence of hepatitis C serum antibody in autoimmune diseases. J Autoimmun (2009) 0.94
Th1/Th2 cytokine imbalance in patients with Sjögren syndrome secondary to hepatitis C virus infection. Semin Arthritis Rheum (2002) 0.94
Primary Sjögren syndrome: hematologic patterns of disease expression. Medicine (Baltimore) (2002) 0.94
Anti-chromatin (anti-nucleosome) autoantibodies. Autoimmun Rev (2002) 0.93
Vitamin K-dependent proteins GAS6 and Protein S and TAM receptors in patients of systemic lupus erythematosus: correlation with common genetic variants and disease activity. Arthritis Res Ther (2013) 0.93
The Relapsing Polychondritis Disease Activity Index: development of a disease activity score for relapsing polychondritis. Autoimmun Rev (2012) 0.92
Antiphospholipid syndrome dilemmas still to be solved: 2008 status. Ann Rheum Dis (2008) 0.92
The epidemiology of systemic lupus erythematosus. Clin Rev Allergy Immunol (2003) 0.92
Epidemiology and management of refractory lupus nephritis. Autoimmun Rev (2011) 0.92
Treat-to-target in systemic lupus erythematosus: where are we today? Clin Exp Rheumatol (2012) 0.91
Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial. Nephrol Dial Transplant (2011) 0.90
Neuropsychiatric systemic lupus erythematosus: magnetic resonance imaging findings and correlation with clinical and immunological features. Autoimmun Rev (2013) 0.90
Unusual manifestations of the antiphospholipid syndrome. Clin Rev Allergy Immunol (2003) 0.89
Osteoporosis in patients with systemic lupus erythematosus. Isr Med Assoc J (2009) 0.89
Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature. Autoimmun Rev (2011) 0.89
Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren's syndrome: prevalence and clinical significance in 335 patients. Clin Rheumatol (2005) 0.88
Behçet's disease in an HIV-1-infected patient treated with highly active antiretroviral therapy. Isr Med Assoc J (2006) 0.88
Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease. Autoimmun Rev (2006) 0.88
Pure sensory neuropathy in primary Sjögren's syndrome. Longterm prospective followup and review of the literature. J Rheumatol (2003) 0.88
Basophils, IgE, and autoantibody-mediated kidney disease. J Immunol (2011) 0.88
Raynaud's phenomenon in primary Sjögren's syndrome. Prevalence and clinical characteristics in a series of 320 patients. J Rheumatol (2002) 0.88
Annual direct medical cost of active systemic lupus erythematosus in five European countries. Ann Rheum Dis (2012) 0.87
Risk factors of vertebral fractures in women with systemic lupus erythematosus. Clin Rheumatol (2009) 0.87
Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse. Clin Rev Allergy Immunol (2009) 0.87
Catastrophic antiphospholipid syndrome: diagnosis and management in pregnancy. Clin Lab Med (2013) 0.87
Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev (2010) 0.87
Systemic lupus erythematosus. Best Pract Res Clin Rheumatol (2010) 0.86
Microangiopathic antiphospholipid-associated syndromes revisited new concepts relating to antiphospholipid antibodies and syndromes. J Rheumatol (2007) 0.86
The relationship between the metabolic syndrome and energy-utilization deficit in the pathogenesis of obesity-induced osteoarthritis. Med Hypotheses (2007) 0.86
Infections and the antiphospholipid syndrome. Clin Rev Allergy Immunol (2009) 0.86
Facts and challenges for the autoimmunologist. Lessons from the second Colombian autoimmune symposium. Autoimmun Rev (2011) 0.86
Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Ann Rheum Dis (2007) 0.85
Clinical features related to antiphospholipid syndrome in patients with chronic viral infections (hepatitis C virus/HIV infection): description of 82 cases. Clin Infect Dis (2004) 0.85
Anti-chromatin (anti-nucleosome) antibodies: diagnostic and clinical value. Autoimmun Rev (2008) 0.85
Peripheral vascular occlusions leading to gangrene and amputations in antiphospholipid antibody positive patients. Ann N Y Acad Sci (2007) 0.84
Microvascular and microangiopathic antiphospholipid-associated syndromes ("MAPS"): semantic or antisemantic? Autoimmun Rev (2007) 0.84
The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol (2007) 0.84
Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus. Clin Rheumatol (2008) 0.83
The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus. Autoimmun Rev (2010) 0.83
HLA class II DNA typing in a large series of European patients with systemic lupus erythematosus: correlations with clinical and autoantibody subsets. Medicine (Baltimore) (2002) 0.83
Circulating monoclonal immunoglobulins in Sjögren syndrome: prevalence and clinical significance in 237 patients. Medicine (Baltimore) (2005) 0.83
Susac's syndrome: an update. Autoimmun Rev (2011) 0.83
Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors. Autoimmun Rev (2006) 0.83